The crossmatch may still be the most clinically relevant histocompatibility test performed.
We evaluated patient sera for flow PRA, FCXM, and end-point donor-antigen titer, and we correlated the results with graft survival. You cannot accurately predict a positive or negative FCXM result-not even when the sera have donor-specific antigens-unless you actually perform a crossmatch. Using fluorescence intensity as a surrogate for antibody concentration does not correlate quantitatively with the occurrence of a positive or negative crossmatch. Therefore, it is imperative to give each recipient a chance at being offered a donor organ by performance of a real-time crossmatch and not rely on a virtual evaluation.
Kerman
Ronald
R
Department of Surgery, Division of Immunology and Organ Transplantation, University of Texas Medical School, Houston, TX, USA.
Lappin
Jacqueline
J
Kahan
Barry
B
Katz
Stephen
S
McKissick
Eva
E
Hosek
Kathleen
K
Acorda
Noriel
N
Wooley
Nicholas
N
Hoover
Angela
A
Miller
Kristah
K
Rodriguez
Luis
L
Moore
Brandt
B
Melcher
Porsha
P
Biedermann
Bridget
B
Van Buren
Charles
C
D005434:Flow Cytometry; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology*; D006650:Histocompatibility Testing / Q000379:methods*; D006801:Humans; D007163:Immunosorbent Techniques; D016030:Kidney Transplantation / Q000276:immunology*; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D014181:Transplantation Immunology; D014184:Transplantation, Homologous